CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
somatotropindrug
Likely dose
somatotropin 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01367834
NCT01367834N/ACompleted
CompareCT.gov

Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome

Rebecca Knickmeyer Santelli, PhD·interventional·Posted Jun 7, 2011·Updated Mar 24, 2017

In Brief

A clinical study evaluating somatotropin for Turner Syndrome. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of this research study is to learn about brain development in very young girls with Turner syndrome (TS) and the effect that growth hormone (GH) therapy has on early brain development.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTurner Syndrome
CountriesUnited States
CollaboratorsPfizer

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2011
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 15.1 years ago

Interventions

somatotropindrug

Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.